Durect Corp.
This article was originally published in The Gray Sheet
Executive Summary
Planned initial public offering would raise funds for R&D, manufacturing and commercialization of pharmaceutical systems combining "delivery technology from the medical device and drug delivery industries with the company's proprietary pharmaceutical and biotechnology drug formulations," the firm says. Underwriters include Morgan Stanley Dean Witter, Chase H&Q and CIBC World Markets